Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 10, 2023 08:00 ET | Source: Morphic Therapeutic

Morphic to Present at November Investor Conferences

WALTHAM, Mass., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
August 29, 2023 08:00 ET | Source: Morphic Therapeutic

Morphic Announces Participation in 2023 Wells Fargo Healthcare Conference

WALTHAM, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
June 06, 2023 16:05 ET | Source: Morphic Therapeutic

Morphic to Present at the Jefferies Global Healthcare Conference

WALTHAM, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
April 25, 2023 07:00 ET | Source: Morphic Therapeutic

Morphic Reports Positive Topline Results of the EMERALD-1 UC Main Cohort; Orally Administered MORF-057 Achieves Primary Endpoint and Demonstrates Clinically Meaningful Improvements Across Secondary and Exploratory Measures

-MORF-057 demonstrates statistically significant reduction of 6.4 points (p=0.002) from baseline at Week 12 in the Robarts Histopathology Index (RHI) Score- -MORF-057 achieves 25.7% clinical...
April 24, 2023 16:01 ET | Source: Morphic Therapeutic

Morphic Therapeutic to Host EMERALD-1 Topline Results Call on April 25, 2023

WALTHAM, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...